08:00 , Mar 3, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Corticotropin-releasing factor receptor 1 (CRHR1; CRFR1)

Neurology INDICATION: Anxiety In vitro and mouse studies identified a CRHR1 antagonist that could help treat anxiety. Chemical synthesis and in vitro testing of benzimidazole analogs identified a compound that bound CRHR1 with a Ki value...
08:00 , Dec 12, 2011 |  BioCentury  |  Emerging Company Profile

Sera Prognostics: Predicting preemies

Sera Prognostics Inc. is developing a molecular test that it thinks will accurately predict more than 90% of women at risk for preterm birth, allowing earlier monitoring and preventive treatment. The company raised $19.3 million...
08:00 , Feb 18, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Approach

Approach Summary Licensing status Publication and contact information Drug delivery Lentiviral-based method of gene therapy to treat CNS disorders A method for delivering and activating genes in the CNS...
07:00 , Sep 20, 2004 |  BC Week In Review  |  Company News

Neurogen, Sanofi-Aventis S.A. deal

The companies will terminate on Dec. 8, their 2001 deal to develop therapeutics against corticotrophin-releasing factor ( CRF1) for stress disorders, including depression and anxiety. The original deal was between NRGN and Aventis S.A.,...
07:00 , Sep 20, 2004 |  BioCentury  |  Finance

Ebb & Flow

The ability of Britain's Arakis to raise £29 million ($52 million) in a series C round has spurred some sector watchers to wonder if this will encourage a spate of investing in European companies that...
07:00 , Sep 15, 2004 |  BC Extra  |  Company News

Neurogen, Sanofi-Aventis ending CRF1 deal

NRGN and Sanofi- Aventis S.A. (Euronext:SAN; SNY) will terminate on Dec. 8 their 2001 deal to develop therapeutics against corticotrophin releasing factor ( CRF1) for stress disorders, including depression and anxiety. The original deal was...
08:00 , Jan 5, 2004 |  BC Week In Review  |  Company News

Neurogen, Aventis deal

NRGN received a $1 million milestone from AVE under the companies' 2001 deal to develop therapeutics against corticotrophin releasing factor ( CRF1). The payment was triggered by a preclinical milestone. Neurogen Corp. (NRGN), Branford, Conn....
08:00 , Dec 24, 2001 |  BC Week In Review  |  Company News

Neurogen, Aventis deal

AVE licensed exclusive worldwide rights to NRGN's corticotrophin releasing factor ( CRF1) antagonist compounds, including its lead, NGD 98-2, for use in treating depression, anxiety and other stress-related disorders. NRGN will receive a $10 million...
08:00 , Dec 20, 2001 |  BC Extra  |  Company News

Neurogen, Aventis CRF1 deal

AVE licensed exclusive worldwide rights to NRGN's corticotrophin releasing factor ( CRF1) antagonist compounds, for use in treating depression, anxiety and other stress-related disorders, including lead compound NGD 98-2. NRGN will receive a $10 million...
07:00 , Jul 1, 1996 |  BC Week In Review  |  Clinical News

Corticotrophin-releasing factor data

NTII announced that Phase I/II testing of CRF reduced symptoms in 6 of 7 patients who received the longest duration of treatment with the factor. Symptoms assessed in the two open-label pilot trials included seizures,...